We’re honored to host Dr. Steve Edelman, T1D, endocrinologist, founder of @TCOYD, who has lived with T1D himself for decades.  He’ll share an honest look at what GLP-1 and other “off-label” medications mean for people with Type 1 diabetes.

There’s a BIG shift in the T1D world: for the first time ever, the ADA’s 2026 Standards of Care now officially support GLP-1 medications for adults living with type 1 diabetes and obesity.

For years, these drugs have been talked about in T1D circles but used off-label, often with a fight to get them prescribed or covered by insurance. Now the guidelines are catching up. But what does that actually mean for you and your care team?

We’ll talk about where they might fit in a care plan (weight, insulin resistance, heart and kidney health), the real risks and open questions, and what this new ADA guidance does and doesn’t change, and how to have a smart conversation with your own care team.